


Partnerships between US and French companies



Bioserenity (France) a medtech company in the Next 40 that specializes in remote diagnostics solutions, acquired **SleepMed** (USA) in 2019 to become a leader of Sleep and Neuroscience diagnostics in the US.



In 2017, French biopharma **Dynacure** (FT 120) licensed a drug for the treatment of centronuclear myopathy (CNM), for which **Ionis Pharmaceutical** (USA) earned a \$5 million license fee in the form of Dynacure equity.



In 2017, **Charles River** (USA) and **ENYO Pharma** (France) together identified the mode of action of ENYO Pharma's lead preclinical chemical series, EYP002, using Charles River's newly acquired, molecular target identification tool: Capture Compound Mass Spectrometry (CCMS) technology.



In 2019, **Orbimed** (USA) invested in French biopharma **Alizé Pharma** (FT 120) and as such, became one of their shareholders. The company completed a €67m series A financing round.



In 2019, **Pfizer Ventures** (USA) has co-led a \$53 million (€48 million) series B investment in **ImCheck** (FT-120), a developer of antibodies focused on gamma delta T cells. **ImCheck** (France) will use the money to move its lead candidate into the clinic in patients with solid and hematological cancers.



A collaboration to co-develop and commercialize Valneva's Lyme disease vaccine candidate. **Valneva** (France) is eligible to receive from **Pfizer** (USA) a total of \$308 million cash payments including a \$130 million upfront payment.

Some R&D collaborations between French and United States during the COVID-19 pandemic



Sanofi (France) & **Regeneron** (USA) expand testing of potential treatment for Covid-19 virus (drug Kevzara).



Valneva (France) & **Dynavax** (USA) announced a collaboration to advance vaccine development for Covid-19.



Sanofi (France) & **Luminostics** (USA) to join forces on developing a breakthrough Covid-19 smartphone-based self-testing solution.